Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Shannon R. McCurdy, MD

Shannon R. McCurdy, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. McCurdy is employed by Penn Medicine.

Request a Callback
No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

Clinical Specialties

Specialty:

  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Internal Medicine, 2012
  • Medical Oncology, 2014

Clinical Expertise:

  • Acute Leukemia
  • Acute Lymphocytic Leukemia in Adults (ALL)
  • Acute Myeloid Leukemia (AML)
  • Allogeneic Transplant
  • Bone Marrow Transplant
  • Chronic Myeloid Leukemia (CML)
  • Chronic Myelomonocytic Leukemia (CMML)
  • Leukemia
  • Myelodysplastic Syndromes (MDS)

Description of Clinical Expertise

While HLA-matched related sibling donors are available for ~30%, they are more difficult to identify for older patients given that their siblings will also be older and often have medical comorbidities that exclude them from donating. In addition, older donor age may be associated with a greater risk of graft failure. As such, I have worked to expand the availability of allogeneic transplantation to older patients through HLA-haploidentical transplantation with post-transplant cyclophosphamide, which allows us to use children, grandchildren, nieces, and nephews as donors. Another former barrier to transplanting older patients was the intensity of conditioning. Historically allogeneic transplantation was limited to patients younger than 50 due to high treatment-related mortality associated with myeloablation. In my work, I demonstrated that utilizing nonmyeloablative HLA-haploidentical transplantation for patients in their 70’s and 60’s yielded similar outcomes to patients undergoing transplantation in their 50’s. In addition to an expertise in allogeneic transplantation, I specialize in the treatment of all phases of care for patients with acute lymphoblastic leukemia and myeloid diseases including acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, and chronic myeloid leukemia.

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Georgetown University School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Johns Hopkins Hospital

Memberships

American Association for Cancer Research, National American Society for Blood and Marrow Transplantation, National American Society of Clinical Oncology, National American Society of Hematology, National

Hospital Affiliation

Dr. McCurdy is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Allogeneic blood or marrow transplantation is the only potentially curative option for patients with relapsed, refractory, or high-risk hematologic malignancies. Unfortunately, only a third of patients have an available HLA-matched related donor. Partially HLA-mismatched related (HLA-haploidentical) transplantation allows identification of a donor for the vast majority of patients. In the past, HLA-haploidentical transplantation was associated with excessive nonrelapse mortality and poor overall survival. My research has contributed to the understanding of a novel technique that utilizes post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after HLA-haploidentical transplantation. Using risk stratification with the disease risk index developed by Armand et al., I demonstrated that outcomes after nonmyeloablative HLA-haploidentical transplantation are comparable to that after reduced intensity HLA-matched transplantation. Similar to my work in older patients described above, I have also shown that nonmyeloablative HLA-haploidentical transplantation is safe and effective for pediatric and young adult patients. In addition, I have contributed to research examining early biomarkers, such as ST2, as predictors of nonrelapse mortality after HLA-haploidentical transplantation. Finally, to improve outcomes further, I have conducted research to examine the association of donor characteristics with transplantation outcomes. I showed that parent donors were associated with more graft failure when compared with sibling or offspring donors, but that survival was no different. Importantly, in that analysis, survival was affected by recipient age with recipients over 55 having inferior survival to younger patients. This work supports my proposed research agenda to evaluate the utility of the frailty phenotype tools to predict an older patient’s risk of nonrelapse mortality after induction chemotherapy and allogeneic transplantation as discussed in this proposal. Finally, my research has contributed to the widespread adoption of HLA-haploidentical transplantation with post-transplant cyclophosphamide, I have advanced the understanding of how we can improve its outcomes further, and I hope to continue to advance the field through studying frailty phenotype assessments in older patients with leukemia and myeloid malignancies undergoing induction then consolidative allogeneic transplantation.

Selected Publications:

McCurdy Shannon R, Muth Stephen T, Tsai Hua-Ling, Symons Heather J, Huff Carol Ann, Matsui William H, Borrello Ivan, Gladstone Douglas E, Swinnen Lode J, Cooke Kenneth R, Brodksy Robert A, Bolaños-Meade Javier, Ambinder Richard F, Varadhan Ravi, Luznik Leo, Jones Rick J, Bettinotti Maria P, Fuchs Ephraim J: Early Fever after Haploidentical BMT Correlates with Class II HLA-Mismatching and Myeloablation but not Outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 35 (26): 2018.

Robinson Tara M, Fuchs Ephraim J, Zhang Mei-Jie, St Martin Andrew, Labopin Myriam, Keesler Daniel A, Blaise Didier, Bashey Asad, Bourhis Jean-Henri, Ciceri Fabio, Ciurea Stefan O, Devine Steven M, Mohty Mohamad, McCurdy Shannon R, Milpied Noel, McNiece Ian K, Rocha Vanderson, Romee Rizwan, Socie Gerard, Yakoub-Agha Ibrahim, Soiffer Robert J, Eapen Mary, Nagler Arnon: Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood advances 2 (11): 1180-1186,2018.

Elmariah Hany, Kasamon Yvette L, Zahurak Marianna, Macfarlane Karen W, Tucker Noah, Rosner Gary L, Bolaños-Meade Javier, Fuchs Ephraim J, Wagner-Johnston Nina, Swinnen Lode J, Huff Carol Ann, Matsui William H, Gladstone Douglas E, McCurdy Shannon R, Borrello Ivan, Gocke Christian B, Shanbhag Satish, Cooke Kenneth R, Ali Syed Abbas, Brodsky Robert A, DeZern Amy E, Luznik Leo, Jones Richard J, Ambinder Richard F: Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24 (5): 1099-1102,2018.

McCurdy Shannon R, Zhang Mei-Jie, St Martin Andrew, Al Malki Monzr M, Bashey Asad, Gaballa Sameh, Keesler Daniel A, Hamadani Mehdi, Norkin Maxim, Perales Miguel-Angel, Reshef Ran, Rocha Vanderson, Romee Rizwan, Solh Melhem, Urbano-Ispizua Alvaro, Waller Edmund K, Fuchs Ephraim J, Eapen Mary: Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood advances 2 (3): 299-307,2018.

McCurdy Shannon R, Kanakry Christopher G, Tsai Hua-Ling, Kasamon Yvette L, Showel Margaret M, Bolaños-Meade Javier, Huff Carol Ann, Borrello Ivan, Matsui William H, Brodsky Robert A, Ambinder Richard F, Bettinotti Maria P, Fuchs Ephraim J, Rosner Gary L, Jones Richard J, Luznik Leo: Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24 (2): 343-352,2018.

McCurdy SR, Kanakry CG, Tsai HL, Bolaños-Meade J, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.: Grade 2 Acute Graft-versus-host Disease Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant (BMT) with Post-Transplant Cyclophosphamide American Society of Hematology Annual Meeting and Exposition (Abstract #216): 2017.

McCurdy Shannon R, Levis Mark J: Emerging molecular predictive and prognostic factors in acute myeloid leukemia. Leukemia & lymphoma : 1-19,2017.

Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R1 O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M.: Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol 23 (26): 3002-3009 ,2017.

Kanakry CG, Bakoyannis G, Perkins SM, McCurdy SR, Vulic A, Warren EH, Daguindau E, Olmsted T, Mumaw C, Towlerton AMH, Cooke KR, O'Donnell PV, Symons HJ, Paczesny S, Luznik L.: Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica 102 (5): 932-940,2017.

McCurdy, SR, Fuchs EJ: Post-transplantation Cyclophosphamide in Haploidentical Transplantation Springer Nature : 2017.

View all publications

Academic Contact Info

Department of Hematology Oncology
3400 Civic Center Blvd

PHILADELPHIA, PA 19063
Patient appointments: 800-789-7366 (PENN)